human bladder cancer, is a putative tumor suppressor. MEG3 acts as a competing endogenous RNA (ceRNA) that binds miR27a releasing its inhibition on tumor suppressor PHLPP2, the latter of which inhibits oncogenes/invasion-promoters c-Jun and c-Myc. Silencing of MEG3 reverses all these tumor-suppressive effects and leads to bladder cancer cell proliferation and invasion.
INTRODUCTION AND OBJECTIVES:
We developed a novel treatment for localized and metastatic bladder cancer comprised of gold nanoparticle-based photothermal therapy and immunotherapy (SYM-PHONY). We demonstrate that it effectively ablates primary tumors, destroys metastases abscopally, and induces potent anti-tumor immunity.
METHODS: MB49 murine bladder cancer cells were injected into the bilateral flanks of C57BL/6 mice and grown until 100 mm3 in size. PEG-functionalized gold nanostars, developed and manufactured by our team, were administered intravenously. A 808-nm laser (0.6 W/ cm2) was used to trigger plasmonic heat production from the gold nanostars in the left flank 24 hours after injection, while the contralateral flank was left untreated. Anti-PD-L1 antibody immunotherapy was coadministered intraperitoneally and repeated q3days. Mice were assessed for ipsilateral and contralateral tumor response and survival. Flow cytometry, multiplex cytokine profiling, and T cell receptor sequencing were used to characterize the immune response. Mice achieving a complete response were rechallenged with an additional injection of MB49 tumor cells 90 days later.
RESULTS: Gold nanostar-mediated phototherapy alone completely ablated ipsilateral tumors in 4/5 of mice (pT0 at necropsy) but contralateral tumors grew and all 5 mice required sacrifice within 14 days. Anti-PD-L1 therapy alone slowed tumor growth in 3/5 mice, but tumors rapidly began growing again and 5/5 mice required sacrifice by 45 days. Combined treatment (i.e. SYMPHONY) ablated 5/5 ipsilateral tumors and resulted in partial (3/5) and complete responses (2/5) of untreated contralateral tumors, demonstrating a strong abscopal effect. After 90 days of follow-up, the two mice achieving a complete response with SYM-PHONY were rechallenged with MB49 and neither developed a tumor over the ensuing 4 weeks indicating strong and effective immune memory. Flow cytometry showed CD4 and CD8 T cell proliferation, decreased myeloid derived suppressor cells, and increased IL2 with SYMPHONY.
CONCLUSIONS: SYMPHONY treatment resulted not only in effective ablation of primary tumors but also in immune-mediated abscopal destruction of untreated distant tumors. Strong and permanent anti-tumor immunity developed in some mice, indicating that with further optimization, SYMPHONY may be able to cure more advanced bladder cancers. 
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INTRODUCTION AND OBJECTIVES:
In this study we performed the first identified quantitative high throughput screening to identify potential targets in urothelial cancer cell lines. We noted a potential new therapy (bardoxolone methyl) and validated this compound with further in vitro studies in cell lines not included in the screen.
METHODS: We screened 8 bladder cancer cell lines against 1,912 oncology-focused drugs using a 48 hr cell proliferation assay with an ATP-based readout (CellTiterGlo), for activity and potency of the compounds in a dose response manner. We identified candidate drugs based on two parameters: 1) more than 70% inhibition at 48 hours 2) a curve class of -1.1/-1.2 indicating curve class with good fit (r2>0.9). Follow up assays in additional cell lines, including viability, spheroid culture, nuclear localization assay, invasion, cell cycle and murine xenograft models were used as confirmation of efficacy and mechanism of the bardoxolone methyl.
RESULTS: Ward clustering analysis of the initial cell lines (figure 1a) along with curve class demonstration (1b) and medication grouping efficacy (1c) is presented here. Among the candidate drugs which were most active in all compounds, bardoxolone methyl was the most attractive based on IC 50 and previous human safety studies. Invasion assays (Figure 2a Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1315
